SAN FRANCISCO, Feb. 9, 2016 /PRNewswire/ -- entrotech life sciences announced that public health and preventive medicine leader and former US Surgeon General, Dr. Kenneth Moritsugu (M.D.,M.P.H, F.A.C.P.M), serves on its Board of Directors. Dr. Moritsugu has nearly 40 years of experience and leadership in patient-centric Public Health and will provide governance for entrotech life sciences for its Preventive Medicine strategies and life-saving technologies, whether in a healthcare setting or on the battlefield.
"There are a multitude of factors contributing to the transformation of delivery of care in the US, including healthcare reform incentives to achieve the triple aim: improve outcomes, lower costs and increase patient satisfaction," said Dr. Moritsugu. "I've joined entrotech life sciences because of the scientific evidence behind its current and future technologies and because the patient is at the center of everything they do."
entrotech life sciences brought its proven track record in advanced materials science to the healthcare industry and created next-generation solutions that work to reduce preventable infections such as Surgical Site Infections (SSIs) and Central Line Associated Bloodstream Infections (CLABSIs), two of the most costly and prevalent issues in healthcare today. ELS invented a patent-pending, non-thermal process for creating polymeric materials containing active chlorhexidine, the most effective antimicrobial for reducing skin bacteria that can cause infection.
Dr. Moritsugu will help entrotech advance its mission to reduce preventable deaths. "We're honored to have Dr. Moritsugu join us on our board," said Jim McGuire, CEO of entrotech. "His track record in healthcare delivery, policy, integrity in evidence-based medicine, and leadership is an asset beyond comparison that will help us in our pursuit to reimagine what's possible in patient care."
About Kenneth Moritsugu
Dr. Kenneth Moritsugu (M.D.,M.P.H, F.A.C.P.M) is Chairman and CEO of First Samurai Consulting, LLC. He is a former Surgeon General of the United States and has held several public health leadership positions with Johnson & Johnson including WorldWide Chairman of the Johnson & Johnson Diabetes Institutes (JJDI) and Vice President for Global Professional Education and Strategic Relations for Johnson & Johnson's Diabetes Solutions Companies. Board Certified in Preventative Medicine, Rear Admiral Moritsugu earned a BA in Classical Languages from the University of Hawaii in 1967, a MD degree from the George Washington University in 1971, and a Master of Public Health from the University of California, Berkeley, in 1975. He holds Fellowships in the American College of Preventive Medicine, the Royal Society of Public Health, the Royal Society of Medicine, and the National Academy of Public Administration. He is an Adjunct Professor of Global Health at the George Washington University Milken School of Public Health, and an Adjunct Associate Professor of Preventive Medicine at the Uniformed Services University of the Health Sciences.
about entrotech life sciences
entrotech life sciences (ELS | San Francisco, CA) helps healthcare professionals committed to infection prevention rethink what is possible in protection of catheter and surgical patients. ELS is affiliated with Entrogroup (est. 1999), an organization focused on inventing advanced lifesaving combat military products, smart device protectors, and environmentally-friendly, lightweight paint appliques. ChloraDerm™, the flagship ELS innovation, is the first and only transparent thin-film dressing with edge-to-edge Chlorhexidine, preventing bacterial regrowth with broad spectrum antimicrobial protection at the wound, primary dressing, or percutaneous medical device site for seven days. Visit: www.entrotechlifesciences.com/chloraderm
SOURCE entrotech life sciences